FZD2: A Potential Drug Target and Biomarker (G2535)

Target Name: FZD2

NCBI ID: G2535

FZD2

FZD2: A Potential Drug Target and Biomarker

Fundamental Genomics and Development

FZD2, short for fast root gene 2, is a gene that plays an important role in the human body. Many scientific studies have shown that FZD2 plays a key role in the pathogenesis of many diseases and has become the target of many drug development. This article will explore the role and possibilities of FZD2 and its potential as a drug target or biomarker.

molecular mechanism

FZD2 is a transcription factor that mainly acts on gene expression and regulation. Studies have found that FZD2 plays an important role in many biological processes, including cell proliferation, apoptosis, cell cycle, epigenetics, etc. In cancer, FZD2 expression levels often change, which may affect tumor cell growth and survival. Therefore, it is very important to study the role of FZD2 in cancer.

Drug Discovery

FZD2 has been the target of many drug developments because they serve as potential targets for the treatment of many diseases. For example, FZD2 has potential applications in treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Many researchers are exploring whether FZD2 could serve as a target for treating other types of cancer.

Biomarkers

FZD2 can also serve as a biomarker to detect disease progression and the effectiveness of treatments. For example, some studies have shown that FZD2 expression levels can serve as a biomarker for the progression of Parkinson's disease. In addition, FZD2 can also be used as a biomarker for recurrence after treatment, which provides important guidance for the treatment of cancer patients.

Clinical application

With the deepening of research, FZD2 has also shown great potential in clinical applications. For example, several clinical trials are exploring FZD2 as a new way to treat neurodegenerative diseases. Additionally, some researchers are exploring FZD2 as a potential biologic to treat other types of cancer.

future outlook

Overall, FZD2 is a very promising drug target with broad clinical application prospects. Future research will continue to delve into FZD2's role in cancer and other biological processes, as well as its potential as a drug target or biomarker. As research deepens, FZD2 will become an important part of future medical development.

Protein Name: Frizzled Class Receptor 2

Functions: Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes (PubMed:25759469). A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues

The "FZD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FZD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets